vs
Side-by-side financial comparison of loanDepot, Inc. (LDI) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $310.3M, roughly 2.0× loanDepot, Inc.). loanDepot, Inc. runs the higher net margin — -7.2% vs -14.8%, a 7.6% gap on every dollar of revenue. On growth, loanDepot, Inc. posted the faster year-over-year revenue change (20.5% vs -10.5%). Over the past eight quarters, loanDepot, Inc.'s revenue compounded faster (18.0% CAGR vs -6.6%).
LoanDepot, sometimes stylized as loanDepot, is an Irvine, California-based nonbank holding company which sells mortgage and non-mortgage lending products.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
LDI vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $310.3M | $619.8M |
| Net Profit | $-22.5M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | -10.3% | — |
| Net Margin | -7.2% | -14.8% |
| Revenue YoY | 20.5% | -10.5% |
| Net Profit YoY | 32.4% | — |
| EPS (diluted) | — | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q4 25 | $310.3M | — | ||
| Q3 25 | $323.3M | $699.9M | ||
| Q2 25 | $282.5M | $613.9M | ||
| Q1 25 | $273.6M | $692.8M | ||
| Q4 24 | $257.5M | $707.8M | ||
| Q3 24 | $314.6M | $727.1M | ||
| Q2 24 | $265.4M | $637.0M |
| Q1 26 | — | $-91.8M | ||
| Q4 25 | $-22.5M | — | ||
| Q3 25 | $-4.9M | $-733.0M | ||
| Q2 25 | $-13.4M | $-255.4M | ||
| Q1 25 | $-21.9M | $-12.7M | ||
| Q4 24 | $-33.2M | $-178.4M | ||
| Q3 24 | $1.4M | $-19.9M | ||
| Q2 24 | $-32.2M | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | -10.3% | — | ||
| Q3 25 | -3.2% | -100.7% | ||
| Q2 25 | -11.4% | -29.4% | ||
| Q1 25 | -16.8% | 4.7% | ||
| Q4 24 | -32.7% | -14.2% | ||
| Q3 24 | 1.1% | 2.1% | ||
| Q2 24 | -29.1% | -18.4% |
| Q1 26 | — | -14.8% | ||
| Q4 25 | -7.2% | — | ||
| Q3 25 | -1.5% | -104.7% | ||
| Q2 25 | -4.7% | -41.6% | ||
| Q1 25 | -8.0% | -1.8% | ||
| Q4 24 | -12.9% | -25.2% | ||
| Q3 24 | 0.4% | -2.7% | ||
| Q2 24 | -12.1% | -23.2% |
| Q1 26 | — | $-1.35 | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-10.78 | ||
| Q2 25 | — | $-3.77 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | — | $-2.54 | ||
| Q3 24 | $0.01 | $-0.30 | ||
| Q2 24 | $-0.18 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $337.2M | $140.4M |
| Total DebtLower is stronger | $2.1B | $2.5B |
| Stockholders' EquityBook value | $386.0M | $1.9B |
| Total Assets | $6.9B | $5.6B |
| Debt / EquityLower = less leverage | 5.44× | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q4 25 | $337.2M | — | ||
| Q3 25 | $459.2M | $98.1M | ||
| Q2 25 | $408.6M | $151.7M | ||
| Q1 25 | $371.5M | $127.1M | ||
| Q4 24 | $421.6M | $98.3M | ||
| Q3 24 | $483.0M | $143.7M | ||
| Q2 24 | $533.2M | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $2.5B | ||
| Q2 25 | $2.1B | $2.1B | ||
| Q1 25 | $2.0B | $2.1B | ||
| Q4 24 | $2.0B | $2.1B | ||
| Q3 24 | $2.0B | $2.2B | ||
| Q2 24 | $2.0B | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $386.0M | — | ||
| Q3 25 | $433.3M | $2.0B | ||
| Q2 25 | $439.1M | $2.8B | ||
| Q1 25 | $469.3M | $3.0B | ||
| Q4 24 | $506.6M | $3.0B | ||
| Q3 24 | $592.0M | $3.2B | ||
| Q2 24 | $578.9M | $3.2B |
| Q1 26 | — | $5.6B | ||
| Q4 25 | $6.9B | — | ||
| Q3 25 | $6.2B | $5.7B | ||
| Q2 25 | $6.2B | $6.4B | ||
| Q1 25 | $6.4B | $6.5B | ||
| Q4 24 | $6.3B | $6.4B | ||
| Q3 24 | $6.4B | $6.8B | ||
| Q2 24 | $5.9B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | 5.44× | — | ||
| Q3 25 | 4.83× | 1.23× | ||
| Q2 25 | 4.70× | 0.74× | ||
| Q1 25 | 4.30× | 0.70× | ||
| Q4 24 | 4.00× | 0.72× | ||
| Q3 24 | 3.31× | 0.68× | ||
| Q2 24 | 3.41× | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-638.7M | — |
| Free Cash FlowOCF − Capex | $-648.0M | — |
| FCF MarginFCF / Revenue | -208.9% | — |
| Capex IntensityCapex / Revenue | 3.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-734.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-638.7M | — | ||
| Q3 25 | $43.4M | $-45.5M | ||
| Q2 25 | $67.6M | $-46.8M | ||
| Q1 25 | $-179.9M | $65.6M | ||
| Q4 24 | $47.7M | $63.7M | ||
| Q3 24 | $-349.2M | $117.9M | ||
| Q2 24 | $-278.3M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-648.0M | — | ||
| Q3 25 | $38.7M | $-94.7M | ||
| Q2 25 | $61.4M | $-84.3M | ||
| Q1 25 | $-186.7M | $9.4M | ||
| Q4 24 | $40.8M | $16.5M | ||
| Q3 24 | $-356.4M | $71.4M | ||
| Q2 24 | $-285.7M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | -208.9% | — | ||
| Q3 25 | 12.0% | -13.5% | ||
| Q2 25 | 21.7% | -13.7% | ||
| Q1 25 | -68.2% | 1.4% | ||
| Q4 24 | 15.8% | 2.3% | ||
| Q3 24 | -113.3% | 9.8% | ||
| Q2 24 | -107.7% | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.0% | — | ||
| Q3 25 | 1.5% | 7.0% | ||
| Q2 25 | 2.2% | 6.1% | ||
| Q1 25 | 2.5% | 8.1% | ||
| Q4 24 | 2.7% | 6.7% | ||
| Q3 24 | 2.3% | 6.4% | ||
| Q2 24 | 2.8% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -255.05× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LDI
Segment breakdown not available.
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
